がんに関連した疲労におけるミトコンドリア機能の役割の評価

Executive Industry Relevance

Mitochondrial dysfunction is increasingly recognized as a mechanistic contributor to cancer-related fatigue, a condition that impacts patient quality of life and may influence treatment tolerance. This protocol enables objective assessment of PBMC mitochondrial function using a compact extracellular flux system, offering a translational tool for de-risking hypotheses in supportive oncology. By providing quantitative readouts such as basal respiration, spare respiratory capacity, and energy phenotype, the method supports target validation and mechanistic insight in fatigue-related pathways.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Enables interrogation of mitochondrial function as a potential therapeutic target in cancer-related fatigue.
• Operational Value: Uses minimally invasive phlebotomy to obtain clinically relevant PBMCs for repeated longitudinal sampling.

Screening & Assay Development

• Scientific Value: Generates quantitative, normalized OCR data that enables comparison across time points and treatment conditions.
• Operational Value: Completes in under 4 hours with standardized normalization to live cell count, supporting assay reproducibility and scalability.

Translational & Preclinical Research

• Scientific Value: Links mitochondrial metrics to clinical fatigue scores, enabling correlation of mechanistic data with patient-reported outcomes.
• Operational Value: Adaptable to other fatiguing conditions, broadening utility across metabolic and inflammatory disease models.

Pipeline & Workflow Integration

The method fits within the discovery continuum by providing functional mitochondrial data that can inform target selection and pathway analysis in fatigue-associated signaling.

• Discovery Biology: Supports hypothesis testing around mitochondrial respiration and energy metabolism in immune cells from fatigued patients.
• Screening: Delivers assay-ready, normalized mitochondrial readouts suitable for evaluating compound effects on OCR and spare capacity.
• Analytics: Provides basal, maximal, and spare respiratory capacity measurements that enable quantitative comparison of mitochondrial phenotypes.
• Translational Research: Connects ex vivo mitochondrial function to in vivo fatigue severity, supporting biomarker-aligned study designs.
• Enterprise Reuse: Establishes a standardized, clinic-compatible workflow for longitudinal immune-metabolic monitoring in oncology cohorts.

Operational & Enterprise Impact

• Scientific Value: Reduces mechanistic ambiguity in cancer-related fatigue by providing direct functional readouts of mitochondrial health.
• Operational Value: Enables standardization across sites via normalization to live cell count and defined inhibitor injection protocols.
• Strategic Value: Supports go/no-go decisions in fatigue-targeted programs by identifying patients with measurable mitochondrial impairment.
• Portfolio Impact: Facilitates risk-stratified advancement of interventions based on objective mitochondrial response to therapy.

Implementation Considerations

• Requires expertise in mitochondrial assay techniques and extracellular flux instrumentation.
• Dependent on access to a calibrated extracellular flux analyzer and sensor cartridges.
• Necessitates standardized training for consistent respiratory inhibitor injection to avoid technical variability.
• Requires optimization of cell density and FCCP concentration for each PBMC donor batch.
• Limited by PBMC viability and functional stability post-isolation, necessitating same-day assay execution.

Biopharma FAQs